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MitoNEET is an outer mitochondrial membrane protein essential
for sensing and regulation of iron and reactive oxygen species (ROS)
homeostasis. It is a key player in multiple human maladies including
diabetes, cancer, neurodegeneration, and Parkinson’s diseases. In
healthy cells, mitoNEET receives its clusters from the mitochondrion
and transfers them to acceptor proteins in a process that could be
altered by drugs or during illness. Here, we report that mitoNEET
regulates the outer-mitochondrial membrane (OMM) protein
voltage-dependent anion channel 1 (VDAC1). VDAC1 is a crucial
player in the cross talk between the mitochondria and the cytosol.
VDAC proteins function to regulate metabolites, ions, ROS, and
fatty acid transport, as well as function as a “governator” sentry
for the transport of metabolites and ions between the cytosol
and the mitochondria. We find that the redox-sensitive [2Fe-2S]
cluster protein mitoNEET gates VDAC1 when mitoNEET is oxidized.
Addition of the VDAC inhibitor 4,4′-diisothiocyanatostilbene-2,2′-
disulfonate (DIDS) prevents both mitoNEET binding in vitro and
mitoNEET-dependent mitochondrial iron accumulation in situ.
We find that the DIDS inhibitor does not alter the redox state of
MitoNEET. Taken together, our data indicate that mitoNEET regu-
lates VDAC in a redox-dependent manner in cells, closing the pore
and likely disrupting VDAC’s flow of metabolites.
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The NEET family of [2Fe-2S] proteins plays essential roles inthe regulation of mitochondrial iron and reactive oxygen spe-
cies (ROS) homeostasis, as well as in the activation of apoptosis,
ferroptosis, and autophagy (1–3). NEET proteins are associated
with several human pathologies including diabetes, cancer,
neurodegeneration, Parkinson’s disease, Wolfram syndrome 2,
and cystic fibrosis (4–9). Many of these pathologies display var-
ious degrees of mitochondrial dysfunction, for which mitoNEET
(mNT) is a critical regulator (10, 11). NEET proteins contain a
signature CDGSH domain and are highly conserved from archaea
to humans (12–14). Each CDGSH domain binds to a redox-active
[2Fe-2S] cluster via a characteristic 3Cys-1His coordination motif
(15, 16). There are 3 human members of the family, mitoNEET
(mNT, CISD1), NAF-1 (ERIS, Miner1, CISD2), and MiNT
(Miner2, Melanoma nuclear protein 13, CISD3). The founding
member of the NEET family, mNT, is a homodimer localized to
the cytosolic side of the outer-mitochondrial membrane (OMM)
by a single-pass N-terminal α-helix per protomer. In addition,
each protomer coordinates a single [2Fe-2S] cluster (16–18). In-
terestingly, mNT can repair the [4Fe-4S] cluster of cytosolic iron-
regulatory protein 1 (IRP1/aconitase), an important regulator of
iron metabolism by either transferring Fe or [2Fe-2S] clusters to it
(19). Mitochondrial-associated mNT also efficiently transfers its
[2Fe-2S] clusters to apo-acceptor proteins such as the CIA im-
portant protein anamorsin (or ciapin1), an electron transfer pro-
tein involved in the assembly of cytosolic Fe-S clusters (16, 20–22).
Although mNT is able to donate its [2Fe-2S] clusters to apo-acceptor
proteins, it remains unclear how mNT is able to exchange Fe-S
clusters with the mitochondria.
VDAC actively governs mitochondrial metabolism and func-
tion through interaction-based gating (23, 24). VDAC plays a
central role in neurodegenerative diseases (e.g., Alzheimer’s
disease) (25–29) and destructive processes (e.g., ROS accumu-
lation) (30–33), as well as regulates apoptotic functions in the
cell (24). mNT’s placement at the OMM with a redox-sensitive
domain suggests that it could be an excellent candidate to
modulate the activity of VDAC. Humans have 3 VDAC paralogs
encoded by 3 separate genes (VDAC1, VDAC2, and VDAC3)
(34, 35), and mNT was identified as an interaction partner with
all 3 forms in multispecies cofractional investigations (36, 37). In
this study, we focus on VDAC1 as it is the most abundant channel
in the mitochondrial membrane, and controls mitochondrial res-
piration as well as transports diverse metabolites and ions (other
than the eponymous anions) between the cytosol and the in-
termembrane space (23, 38, 39). VDAC controls passage of me-
tabolites between the cytosol and mitochondrial intermembrane
space via modulation of different open and closed states of the
protein (40). VDAC1 expression level is controlled independently
of the expression level of VDAC2 and VDAC3 (41). Therefore, in
this study, we characterize the effect of VDAC1 (hereafter re-
ferred to as VDAC) interactions with mNT.
Our studies indicate that mNT regulates the channel function
of VDAC and that this interaction is dependent on the redox
state of mNT’s [2Fe-2S] clusters. Additionally, using a combination
of hydrogen–deuterium exchange mass spectrometry (HDX-MS)
and computational docking methodologies, we identify the pro-
tein–protein interaction regions involved in the association
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between mNT and VDAC. Importantly, we demonstrate that the
VDAC inhibitor 4,4′-diisothiocyanatostilbene-2,2′-disulfonate
(DIDS), which blocks VDAC via an initial reversible reaction
followed by irreversible cross-linking (42, 43), abrogates the
binding of mNT to VDAC in vitro and also prevents mNT from
transferring its Fe/[2Fe-2S]s in situ. In addition, DIDS does not
alter the redox state of mNT. Taken together, our results un-
derscore the relevance of the redox-dependent interaction be-
tween mNT and VDAC in maintaining cellular homeostasis and
the regulation of Fe and [2Fe-2S] clusters in cells.
Results and Discussion
High Affinity and Redox Modulation of VDAC–mNT Interaction. Mi-
croscale thermophoresis (MST) was employed to quantify the affinity
of the VDAC–mNT interaction. Fluorescently labeled human VDAC
in dimyristoyl phosphatidylcholine (DMPC)/3-[(3-cholamidopropyl)
dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO)
bicelles (1% final concentration) was incubated with increasing
concentrations of mNT and analyzed by MST, and a dissociation
constant (Kd) of 76 ± 2 nM of mNT for VDAC was determined
(Fig. 1). Reduction with dithiothreitol (DTT) prevented any de-
tectable binding of mNT to VDAC, indicating that mNT binds to
VDAC when its [2Fe-2S] clusters are oxidized (e.g., when the
protein or lysates are exposed to oxygen; Fig. 1). The dependency
of the interaction of mNT–VDAC on the oxidation state of mNT
suggests that it may be part of a response to oxidative stress, as the
redox-active mNT is typically in a reduced state under normal
cellular conditions (44, 45). Due to its redox potential (Em,7) of
+30 mV, mNT can be oxidized under conditions such as cell stress
in disease states, defense, or cell death (46, 47).
The VDAC channel adopts a high-conductance “open” state,
as well as several low-conductance “closed” states. When VDAC
adopts a closed conformation (48), it inhibits ATP flux across the
channels. In addition, VDAC channel permeability is regulated
by binding to Bcl2 family proteins, hexokinase and tubulin (48–
50). As mNT interacts with both proapoptotic and antiapoptotic
proteins in the BCL family, we explored the role of mNT in
regulating VDAC function. VDAC conductance was recorded
both in the absence and presence of mNT across a range of
applied voltages. The characteristic VDAC voltage-dependent
conductance pattern is observed in the absence of added mNT
protein, with decreasing conductance as voltage is increased
above ∼35 mV (both positive and negative), as expected (40, 51)
(Fig. 2). In the presence of mNT, the observed channel conduc-
tance is significantly inhibited across the entire voltage spectrum
as compared to that observed in the absence of added protein
(Fig. 2). In contrast, the presence of NAF-1, a related NEET
protein, had a smaller effect on the conductance changes across
the voltage range, and this protein may have a separate function
associated with the truncated VDAC-ΔC form (19).
Structural Analysis of the VDAC–mNT Interaction.We utilized HDX-
MS to interrogate the interaction interface between mNT and
VDAC. Backbone amide protons in both proteins provide
probes for interactions as they can be protected from exchange
with the solvent at the binding interface, as well as cause changes
in deuterium exchange rates at sites distal to the binding in-
terface (52). Analyzing the monomeric VDAC–nanodisc com-
plex (VDAC–cND) allowed us to investigate affects arising
solely from the interaction of VDAC with mNT. MST binding
analysis indicates that oxidized mNT binds to VDAC with a Kd of
210 ± 15 nM (SI Appendix, Fig. S1). In order to interrogate the
protein–protein interface, protease digestion after defined time
periods of HD exchange with interaction were performed. Di-
gestion of mNT produces 125 peptide probes and high (89%)
sequence coverage. Digestion of the integral membrane protein
VDAC also results in high sequence coverage, with a total of 91
peptide probes covering this integral membrane protein. Com-
parative heat map representations of the hydrogen–deuterium
exchange kinetics of apo and complexed mNT and VDAC are
provided in SI Appendix, Figs. S2 and S3. Deuterium incorpo-
ration plots for representative peptide probes within regions that
display significant changes in protection upon complex formation
are shown for both mNT and VDAC. The regions displaying
changes in exchange protection are highlighted on the respective
protein structures in Figs. 3 and 4. The regions of mNT with
increased protection upon complex formation include the [2Fe-2S]
cluster-binding region, the strand swapped outer β-strand, and
the α-helix within the cluster binding domain (16). VDAC pro-
tection increases at loop regions on the cytosolic side of the pore,
with 3 consecutive loops on the C-terminal end of the barrel and
1 loop juxtaposed across the surface. The N-terminal helix inside
the pore that stabilizes the barrel is unaffected by the binding of
mNT, suggesting that mNT does not bind deep enough into the
barrel to alter exchange within this region, which still exchanges
freely with solvent. Notably, peptides with increased protection
upon complex formation extend down the side of the VDAC
barrel, opposite the internal helical region. These observed changes
in exchange protection may indicate that mNT forms contacts
further down the side of the barrel opposite the internal helix, or
Fig. 1. mNT binding to VDAC is redox state dependent. MST analysis used
to assess the affinity of mNT to fluorescently labeled VDAC reconstituted in
1% DMPC/CHAPSO bicelles under oxidizing conditions results in measured
Kd of 76 ± 2 nM (black). When mNT is reduced with DTT, binding is not
observed (red).
Fig. 2. VDAC channel conductance is inhibited by mNT. VDAC was recon-
stituted into a planar lipid bilayer and channel conductance was measured as
a function of applied voltage. The recordings were taken before and after
the addition of 5 μg/mL mNT (A) or NAF-1 (B). Conductance measurements
were normalized to the conductance at 10 mV using the following formula:
G/Gmax = (Conductance/Maximal Conductance of Control).
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that changes in local motions from binding are extended down
the barrel wall. Taken together, these data indicate that mNT
binds across the cytosolic side of the VDAC channel and partially
into the barrel.
In investigations independent of the HDX-MS experiments,
we performed computational docking analysis of the 2 proteins
(SI Appendix, Fig. S4). In the final docked complex, mNT fits
asymmetrically into the VDAC channel with one mNT [2Fe-2S]
cluster-binding domain contacting the cytosolic loops of VDAC,
above the N-terminal helix. The β-cap of mNT is positioned in
between the N-terminal helix (but not contacting it) and di-
ametrically opposed to the helix barrel wall of VDAC. This
docked model matches well with our experimental data, sup-
porting a likely mode of protein–protein interaction.
The VDAC Inhibitor DIDS Prevents Both mNT–VDAC Binding and
Influences Iron/Fe-S Flux between mNT and the Mitochondria. The
binding of mNT and VDAC in vitro was interrogated in the
presence of a known inhibitor of VDAC channels, with MST
analysis. Fluorescently labeled VDAC in phospholipid bicelles
was pretreated with DIDS followed by MST analysis of mNT
binding. The presence of DIDS completely prevented detectable
binding of mNT to VDAC (Fig. 5A) while not affecting the redox
state of mNT (SI Appendix, Fig. S5). Given this observation, we
then determined whether inhibiting the interaction would prevent
the transfer of iron into the mitochondria in situ, as we previously
discovered that addition of oxidized mNT to gently permeabilized
cells results in influx of iron into the mitochondria (2). Soluble
mNT was added to gently permeabilized h9c2 cells. Rhodamine
B-[(1,10-phenanthrolin-5-yl)-aminocarbonyl] benzyl ester (RPA)
was used as an indicator of mitochondrial iron. We monitored the
change in fluorescence in response to addition of mNT in situ.
RPA is rapidly quenched following addition of mNT, indicating
transfer of iron into mitochondria. Although these studies are not
under physiological conditions, they demonstrate that mNT
binding to VDAC can also occur within the cellular environment
(Fig. 5B). Notably, in the presence of the VDAC inhibitor DIDS,
the quenching of RPA is significantly reduced (Fig. 5B).
Fig. 6 reconciles all experimental and computational analyses
to create a representative model of the complexed mNT and
VDAC proteins. VDAC transports metabolites, such as ATP,
ADP, pyruvate, and fatty acids, across the OMM between the
cytosol and intermembrane space. One effect of VDAC closure
is inhibited fatty acid metabolism in the mitochondria, leading
to lipid accumulation in the cytosol. Fatty liver disease (liver
steatosis) and chronic ethanol exposure are associated with insulin
resistance (53, 54), while insulin resistance and alcohol metabo-
lism are also associated with oxidative stress (55, 56). A recent
study demonstrated that the genetic knockout of mNT prevented
liver steatosis in ethanol-fed mice (57). Moreover, exposure to
Fig. 3. Regions of mNT with increased protection upon interaction with
VDAC. Selected plots of deuterium incorporation into peptides from regions
with significant increases in protection upon complex formation are shown.
An additional plot is given (peptide 93 to 108) that is representative of a
region with no significant change in deuterium incorporation upon complex
formation. Regions that exhibit significant increases in HD-exchange pro-
tection are highlighted on the mNT crystal structure (PDB ID code 2QH7) in
blue, while regions with similar protection factors are shown in beige.
Fig. 4. Regions of VDAC with increased protection upon interaction with
mNT. Selected plots of deuterium incorporation into peptides from regions
with significant increases in protection upon complex formation are shown.
An additional plot is given (peptide 2 to 25) that is representative of pep-
tides with no significant change in deuterium incorporation upon complex
formation. This unaffected peptide corresponds to the N-terminal α-helix
inside the VDAC barrel. Regions that exhibit significant increases in HD-
exchange protection are highlighted on the VDAC crystal structure (PDB ID
code 5XDO) in blue, and those without changes are in beige.
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ethanol induces a decrease in mitochondrial function via VDAC
closure (58). This effect results in a reduction of mitochondrial
ATP production, as well as in inhibition of fatty acid oxidation
(58). We have shown with perturbation studies that soluble mNT
added to permeabilized cells could transfer its Fe/[2Fe-2S] cluster
directly into the mitochondria (1, 2). We now show that addition of
the VDAC inhibitor DIDS prevents the mitochondrial Fe/[2Fe-2S]
accumulation with the addition of soluble mNT, indicating that the
interaction with VDAC provides one conduit for this transfer. Our
results suggest that, under oxidative stress that could be induced
by different sources, VDAC channels are blocked by binding of
oxidized mNT with nanomolar affinity and this binding limits
channel conductance by favoring the closed state of the channel.
Binding of the type 2 diabetes drug pioglitazone stabilizes the
oxidized [2Fe-2S] cluster against release (16) and could inhibit the
transfer of iron into the mitochondria (21). However, it must be
stated that pioglitazone binding can cause a bottleneck in cytosol/
mitochondrial cross talk and also inhibit the biologically relevant
transfer of iron out of the mitochondria and promote ROS ac-
cumulation as we have shown in cancer cells (5).
Because mNT has a redox-active [2Fe-2S] cluster, is linked to the
glutathione system, and protects cardiomyocytes from oxidative-
stress–mediated apoptosis, it may have a role in cellular redox
sensing (16, 21, 59, 60). This idea is further supported by a number
of studies showing that mNT’s [2Fe-2S] cluster transfer occurs in the
more labile, oxidized state (12, 21, 61, 62). Therefore, it is perhaps
unsurprising that only oxidized mNT binds VDAC. However, cell
death, stress, or defense conditions can change the cellular redox
state, through ROS by-products of disrupted oxidative phosphory-
lation, leading to a reduction of the [2Fe-2S] clusters in mNT (45,
63–65). Such redox-dependent binding supports a proposal that the
[2Fe -2S] clusters of mNT act as an on/off switch accompanied by
profound alterations of its protein interactions and cellular function.
With the mitochondria being the largest source of superoxide and
other ROS in the cell, mNT is in ideal proximity for redox sensing
and cytosolic communication due to its strategic location on the
OMM facing the cytosol (66–69). Our results establish an im-
portant interaction between mNT and VDAC in the OMM that
occurs under oxidative conditions. This interaction is potentially
part of a stress response that can result in cell death by ferroptosis
and may also be a potential source of mitochondrial iron overload
during oxidative stress (6, 54, 70).
Materials and Methods
Expression and Purification of Human mNT and VDAC. Human mNT was
expressed and purified as described (21). Recombinant human VDAC with a
C-terminal 6×His tag was expressed as described (71). Nanodiscs containing
VDAC were prepared using the covalently circularized cNW9 scaffold protein
and DMPC/DMPG at a 3:1 ratio as described (72).
MST. Purified VDACwas fluorescently labeled using the amine reactive RED-NHS
NT-647 dye (NanoTemper) according to the manufacturer’s protocol, and was
studied both in lipid bicelles as well as covalently circularized nanodiscs (cND)
Fig. 5. DIDS inhibits mNT–VDAC interaction. (A) MST analysis of the effect of DIDS on the binding of mNT to fluorescently labeled VDAC in 1% DMPC/
CHAPSO bicelles under oxidizing conditions. The final DIDS concentration following mNT addition was 700 μM. (B and C) The effect of DIDS on mNT-induced
changes in mitochondrial iron levels. H9c2 cells were preincubated with and without DIDS (100 μM) for 1 h, labeled with RPA, and permeabilized with
digitonin to allow the entry of mNT into cells. The change in RPA fluorescence was followed every 5 min. Twenty micromolar mNT was added after 10 min.
Five micromolar ferrous ammonium sulfate, complexed to equimolar hydroxyquinoline (FeHQ), which is a siderophore that allows iron to pass the membrane,
was added after 45 min. RPA fluorescence is expressed in relative units (r.u.) obtained by analyzing individual cell fluorescence with ImageJ (open software),
by averaging 5 cells per field.
Fig. 6. Combined experimental and computational model of mNT docked
to VDAC. Data from HDX-MS experiments and Fd-DCA calculations were
combined to generate a model for the docking of the mNT dimer inside the
VDAC pore. Increased protection mapping is indicated by darker blues,
minimal protection by light blues, and no protection by tan. VDAC PDB ID
code, 5XDO; MNT PDB ID code, 2QH7.
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(72). The DMPC/CHAPSO (3:1) bicelle mixture was added to the fluorescently
labeled VDAC (in lauryldimethylamine oxide [LDAO] micelles) to a concentra-
tion of 2% and incubated on ice for 30 min. The VDAC-bicelle mixture was
diluted to 50 nM in 50mMphosphate buffer, 100 mMNaCl, 2% bicelles, pH 7.0.
VDAC was also assembled in the cNDs recently described by Nasr et al. (72),
which incorporates a single VDAC protein in each nanodisc. Nanodiscs con-
taining VDAC were fluorescently labeled in lipid bicelles, in the same manner as
described above. MST analysis was performed at 22 °C using a Monolith NT.115
system (NanoTemper) using a constant concentration of labeled VDAC in either
bicelles or nanodiscs and a 1:1 serial dilution of mNT in 50 mM sodium phos-
phate, 100 mM NaCl, pH 7.0. MST analysis of VDAC bicelles with reduced mNT
was performed in the same buffer at pH 8.0 with the addition of 20 mM DTT.
Replicate MST measurements were collected for all VDAC-bicelle and VDAC-
nanodiscs mNT binding studies. Small-molecule inhibitor binding of DIDS was
performed with preincubation of VDAC with a DIDS concentration of 700 μM
(the 10-fold concentration above the 70 μM KD of VDAC with DIDS reflects
conditions where 99.9% of VDAC is bound with DIDS).
Data were normalized and fit to the Hill equation with a Hill coefficient >1
using KaleidaGraph software (Synergy Software).
Gating Experiments.VDAC from sheep liver mitochondriawas solubilizedwith
LDAO and purified using hydroxyapatite resin as described previously (73).
The purified VDAC was used for channel reconstitution into a planar lipid
bilayer. Sheep liver were chosen as the source for VDAC as it exhibits 99.3%
sequence identity with the human protein (74) (SI Appendix, Fig. S6). VDAC
was added to the patch clamp cis chamber containing 0.5 M NaCl and 10 mM
Hepes, pH 7.4. After one or more channels were inserted into the planar
lipid bilayer, currents were recorded by voltage clamping using a Bilayer
Clamp BC-525B amplifier (Warner Instruments). Current was measured with
respect to the trans side of the membrane (ground) in the presence and
absence of purified mNT and NAF-1. The current was digitized on-line using
a Digidata 1200 interface board and pCLAMP 6 software (Axon Instruments).
Cellular Studies. Given the observation that DIDS inhibits the binding of mNT
to VDAC in vitro, we then determined whether inhibiting the interaction
would prevent the transfer of iron into the mitochondria in situ. As we
previously discovered via perturbation studies, the addition of oxidized mNT
to gently permeabilized cells results in an influx of iron into the mitochondria
(21). Soluble, oxidized mNT was added to gently permeabilized h9c2 cells.
Using RPA as an indicator of mitochondrial iron, we monitored the change
in fluorescence in response to addition of mNT.
Stability Analysis. The potential effect of the lipids and interaction of VDAC on
the cluster stability mNT was assessed following the absorption of the [2Fe-2S]
clusters over time as described previously (2, 15, 16, 70, 75). Briefly, 25 μMmNT
was incubated in the presence of 25 μM empty nanodiscs (negative control) as
well as 25 μM nanodiscs containing VDAC in 50 mM sodium phosphate,
100 mM NaCl, pH 7.0, at 37 °C. The absorbance at 458 nm was monitored as a
function of time as previously published (12, 62, 70, 76).
HDX-MS. To elucidate the regions important for the interactions between
oxidized mNT and VDAC, we first determined the optimum conditions for
final mass spectral analysis of HDX-MS. In an effort to get the maximum
coverage of both proteins, we explored a range of denaturant conditions,
proteases, and pHs for final analysis as described (77–83). Our HDX experi-
ments were carried out in 10 mM sodium phosphate, 100 mM NaCl, pH 7.0,
with a final D2O concentration of 90%. The hydrogen–deuterium exchange
reaction was quenched at 4 °C with a final concentration of 500 mM
guanidine-HCl, 0.5% formic acid, and 10% glycerol in D2O and flash frozen.
Samples were stored at −80 °C until analyzed. Instrument setup and oper-
ation were described previously (84). Both porcine pepsin and fungal pro-
tease XIII were used to enhance peptide coverage. Peptides were identified
using Sequest software (Thermo Finnigan). Each peptide was evaluated at
every time point for quality control. Deuterium content for each time point
was calculated using DXMS Explorer (Sierra Analytics).
Computational Methodology. Our protein–protein binding site identification
method, Fd-DCA (fragment docking–direct coupling analysis), was used to
predict the highest probability mNT–VDAC binding sites from coevolving
residues (85). These residue–residue couplings were taken as constraints for
modeling the initial energetically favorable binding complex of mNT–VDAC
(83). I-TASSER was used to model the N-terminal transmembrane domain
(residues 14 to 31) of mNT as an α-helix, since it was not available in the
crystal structure (86). Then the modeled molecular structure of mNT was
explored to identify candidate binding sites for protein–protein interaction.
As a result, 3 sites were obtained, as shown in SI Appendix, Fig. S7. The
largest binding site, designated as site 1, covers the 2Fe-2S cluster region.
Site 2 is adjacent to the membrane domain, and site 3 is relatively small and
located in the β-cap domain, under site 1. To discriminate which binding site
of mNT interacts with VDAC, DCA was performed between mNT and VDAC.
The sequences of mNT were collected from UniProt (13, 87). The sequence
alignment of VDAC was obtained from Jackhmmer (88) by using the fast
sequence of the Protein Data Bank (PDB) entry (5XDO) of VDAC as the
template. To join these 2 sequence alignments, we followed the same rules
presented in our previous work (85). The predicted top 20 coevolving residue
pairs between the 2 proteins are listed in SI Appendix, Table S1. In-
terestingly, a part of these coevolving signals are across the soluble domain
of mNT and VDAC, and the other part is from the membrane domain of mNT
and VDAC. Meanwhile, as shown in SI Appendix, Table S1 and Fig. S3, these
predicted coevolving residues of mNT are largely overlapped with the residues
on identified site 1 and site 2. This indicated that VDAC could interact with
both binding sites of mNT. Taking these top 20 coevolving residue pairs as the
constraints, we docked mNT into VDAC to create a binding complex and used
a Steepest Descent (SD) energy minimization from Gromacs v5.0.5MD to op-
timize a final, complex structure, shown in SI Appendix, Fig. S8.
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